ReviewAge and ageing2024
New Horizons in Peripheral Artery Disease.
Review in Age and ageing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Accelerated biological aging, genetic susceptibility, and the risk of peripheral arterial disease: Evidence from the UK Biobank cohort study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Endothelial Cells Offer a Better Option than Smooth Muscle Cells for the Treatment of Ischemic Limb Disease.Cells · 2026Article
- Comparative Efficacy of Endovascular Interventions for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.Cardiovascular and interventional radiology · 2026Review
- Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.European heart journal · 2026Article
- Mechanically Robust Biodegradable Stents With Theragenerative Vascular Responses via Combined 3D Printing and Janus Nanoengineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Indoleacrylic acid mitigates vascular rarefaction and enhances ischemia-induced neovascularization in aging via APLNR signaling.Acta pharmacologica Sinica · 2026Article
- Directional Atherectomy Versus Plain Old Balloon Angioplasty for Vessel Preparation Before Drug-Coated Balloon Treatment in Moderate-to-Severe Calcified Lesions.Cardiovascular and interventional radiology · 2026Article
- Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions.Annals of medicine and surgery (2012) · 2026Article
- Smart Antibiofilm Platforms Based on Synthetic Antimicrobial Peptides-Engineered Hydrogels.Polymers · 2026Review
- Impact of comorbid depression on clinical outcomes in patients with peripheral artery disease: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Article
- Ultrasound-guided continuous parasacral ischial plane block for diabetic foot ulcer healing: study protocol for a single-centre, prospective, randomised, open-label, blinded-endpoint controlled trial.Frontiers in endocrinology · 2026Article
- Trends of the burden, risk factors, and future projections of peripheral artery disease in the elderly.BMC geriatrics · 2025Article
- The relationship between C-reactive protein-albumin-lymphocyte index and peripheral artery disease.Scientific reports · 2025Article
- Article
- Global, regional, and national trends in peripheral arterial disease among older adults: findings from the global burden of disease study 2021.Aging clinical and experimental research · 2025Article
- What Is the Best Experimental Model for Developing Novel Therapeutics in Peripheral Artery Disease?Arteriosclerosis, thrombosis, and vascular biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral artery disease (PAD) is the lower limb manifestation of systemic atherosclerotic disease. PAD may initially present with symptoms of intermittent claudication, whilst chronic limb-threatening ischaemia (CLTI), the end stage of PAD, presents with rest pain and/or tissue loss. PAD is an age-related condition present in over 10% of those aged ≥65 in high-income countries. Guidelines regarding definition, diagnosis and staging of PAD and CLTI have been updated to reflect the changing patterns and presentations of disease given the increasing prevalence of diabetes. Recent research has changed guidelines on optimal medical therapy, with low-dose anticoagulant plus aspirin recommended in some patients. Recently published randomised trials highlight where bypass-first or endovascular-first approaches may be optimal in infra-inguinal disease. New techniques in endovascular surgery have increased minimally invasive options for ever more complex disease. Increasing recognition has been given to the complexity of patients with CLTI where a high prevalence of both frailty and cognitive impairment are present and a significant burden of multi-morbidity and polypharmacy. Despite advances in minimally invasive revascularisation techniques and reduction in amputation incidence, survival remains poor for many with CLTI. Shared decision-making is essential, and conservative management is often appropriate for older patients. There is emerging evidence of the benefit of specialist geriatric team input in the perioperative management of older patients undergoing surgery for CLTI. Recent UK guidelines now recommend screening for frailty, cognitive impairment and delirium in older vascular surgery patients as well as recommending all vascular surgery services have support and input from specialist geriatrics teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.